Beyond HAART Innovative Therapies to Control HIV 1 (P01) | Apply Online

Opportunity Summary:

Beyond HAART Innovative Therapies to Control HIV-1 (P01) is an NIH funding opportunity sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) together with the National Institute of Mental Health (NIMH). It was released as RFA-AI-11-012 and uses the P01 program project grant mechanism, which is meant for multi-project, highly coordinated research efforts rather than a single stand-alone study. The central aim is to push HIV treatment beyond lifelong antiretroviral therapy (commonly referred to as HAART) by supporting the development of therapeutic strategies that could let people living with HIV-1 stop their current medications for a meaningful, sustained period without the virus rebounding.

The scientific focus is on innovative interventions intended to control HIV-1 in the absence of continuous standard therapy. The announcement highlights several categories of approaches of particular interest, including therapeutic vaccines (designed to strengthen or redirect immune responses against HIV), gene therapies (such as genetic modifications that make cells resistant to infection or that target viral persistence), cell-based therapies (including engineered or adoptively transferred immune cells), antibody-based approaches (for example, targeted antibodies that neutralize virus or help clear infected cells), and other targeted interventions that could plausibly contribute to long-term viral control. The emphasis is not simply on managing infection while on drugs, but on achieving durable control when conventional therapy is paused.

A defining feature of the FOA is its expectation that funded teams will combine basic and translational work in one integrated program. Applicants are expected to carry out foundational research needed to understand and optimize their chosen approach, while also moving toward practical demonstration through translational activities. These translational elements can include proof-of-concept studies, which may be conducted in relevant animal models and, where appropriate and feasible, in human studies. In other words, the program is designed to support a pipeline from mechanistic discovery and platform development through early-stage testing that demonstrates whether a strategy has real potential to prevent viral rebound after treatment interruption.

Collaboration is treated as a requirement rather than a preference. Program project applications under this FOA must be structured as joint efforts between academic researchers and private-sector partners. This reflects an intent to accelerate development and real-world applicability by combining academic strengths in discovery science with industry strengths in product development, manufacturing considerations, regulatory planning, and translation to clinical settings. Because the mechanism is a program project, applicants typically need to organize multiple interrelated research projects and shared resources (often called cores) around a single unifying theme, with clear synergy across the components.

In terms of eligibility, the opportunity was broadly open to a wide range of U.S.-based organizations, including public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, small businesses, and multiple levels of government entities (state, county, city/township, special district). It also explicitly included organizations such as historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian serving institutions, faith-based and community-based organizations, and eligible federal agencies. Foreign organizations were not eligible to apply as primary applicants; however, foreign components could participate as part of a larger program project application led by a domestic U.S. institution, meaning specific projects or shared cores could be based at foreign institutions if included under a U.S. prime applicant.

Administratively, this was a discretionary grant opportunity in the health research category, associated with CFDA numbers covering mental health research grants (93.242) and infectious disease, immunology, and transplantation research (93.855 and 93.856). The FOA did not require cost sharing or matching. Key dates listed include a posted and creation date of April 20, 2011, with an original and current closing date of July 19, 2011, and an archive date of August 19, 2011. The full announcement was hosted through the NIH grants guide, and technical access issues were directed to the NIH Office of Extramural Research (OER) webmaster contact listed in the notice.

Overall, the grant opportunity was designed to fund coordinated, multi-team programs that could deliver credible, testable paths toward functional control of HIV-1 without continuous antiretroviral therapy, prioritizing approaches that blend innovation with a clear plan for translation and that are built on strong academia-industry partnerships.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Lifespan Respite Care Program Competing Program Expansion Supplements

Previous opportunity: Community Development Block Grant Program for Indian Tribes and Alaska Native Villages (ICDBG)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA AI 11 012

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA AI 11 012) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 11 012", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.